New pill HRS7415 shows promise in early cancer trial

NCT ID NCT05318833

Completed Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called HRS7415 in 38 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see if the drug could help control the disease. Researchers monitored side effects and measured drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS7415
What this could lead to: If it works, this could point toward a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 38 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMOR

Contacts and locations

Locations

Cancer Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, 250021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.